Post by Drug Hunter

Ropsacitinib (PF-06826647) is a TYK2 inhibitor that reached Ph. 2 development in plaque psoriasis and hidradenitis suppurativa. What made it especially interesting was its mechanism: unlike deucravacitinib (Sotyktu®), which binds the TYK2 JH2 pseudokinase domain allosterically, ropsacitinib targeted the catalytically active JH1 domain—an ambitious strategy given how conserved the JAK ATP-binding site is. Despite encouraging psoriasis data, ropsacitinib does not appear to be in active development today, while Priovant’s dual JAK1/TYK2 inhibitor brepocitinib has become the clearer priority.